PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
27358233-1	2017	N-Benzylpiperazine (BZP) and 1-(3-trifluoromethylphenyl)piperazine (TFMPP) are two synthetic phenylpiperazine analogues that have been frequently commercialized in combination as an alternative to ecstasy ("Legal X").	phenylpiperazine	93-109	zinc finger E-box binding homeobox 1	Homo sapiens	20-23
27658794-0	2016	Synthesis of phenylpiperazine derivatives of 1,4-benzodioxan as selective COX-2 inhibitors and anti-inflammatory agents.	phenylpiperazine	13-29	prostaglandin-endoperoxide synthase 2	Homo sapiens	74-79
25648298-0	2015	Discovery of phenylpiperazine derivatives as IGF-1R inhibitor with potent antiproliferative properties in vitro.	phenylpiperazine	13-29	insulin like growth factor 1 receptor	Homo sapiens	45-51
26349898-0	2015	Discovery of a series of novel phenylpiperazine derivatives as EGFR TK inhibitors.	phenylpiperazine	31-47	epidermal growth factor receptor	Homo sapiens	63-67
26349898-2	2015	We report herein the discovery of a novel class of phenylpiperazine derivatives with improved potency toward EGFR.	phenylpiperazine	51-67	epidermal growth factor receptor	Homo sapiens	109-113
25648298-5	2015	These studies confirmed that these new phenylpiperazine derivatives maintain their mechanisms of action by disrupting IGF-1R kinase.	phenylpiperazine	39-55	insulin like growth factor 1 receptor	Homo sapiens	118-124
24211020-2	2013	In the course of our studies to determine the optimal substituents in the sigma2-selective phenyl piperazines analogues with reduced activity at other neurotransmitter systems, we discovered that 1-(3-chlorophenyl)-4-phenethylpiperazine actually had preferentially increased affinity for dopamine transporters (DAT), yielding a highly selective DAT ligand.	phenylpiperazine	91-109	solute carrier family 6 member 3	Homo sapiens	288-309
24211020-2	2013	In the course of our studies to determine the optimal substituents in the sigma2-selective phenyl piperazines analogues with reduced activity at other neurotransmitter systems, we discovered that 1-(3-chlorophenyl)-4-phenethylpiperazine actually had preferentially increased affinity for dopamine transporters (DAT), yielding a highly selective DAT ligand.	phenylpiperazine	91-109	solute carrier family 6 member 3	Homo sapiens	311-314
24211020-2	2013	In the course of our studies to determine the optimal substituents in the sigma2-selective phenyl piperazines analogues with reduced activity at other neurotransmitter systems, we discovered that 1-(3-chlorophenyl)-4-phenethylpiperazine actually had preferentially increased affinity for dopamine transporters (DAT), yielding a highly selective DAT ligand.	phenylpiperazine	91-109	solute carrier family 6 member 3	Homo sapiens	345-348
23019496-2	2012	Drugs of abuse such as MDMA (streetname "ecstasy") and certain 1-phenyl-piperazine (PP) analogs such as 1-(3-chlorophenyl)-piperazine (mCPP) elicit their stimulatory effect by elevating the synaptic concentration of serotonin by blocking or reversing the normal transport activity of hSERT.	phenylpiperazine	63-82	solute carrier family 6 member 4	Homo sapiens	284-289
23766142-0	2013	Fos expression in response to dopamine D3-preferring phenylpiperazine drugs given with and without cocaine.	phenylpiperazine	53-69	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	0-3
21602603-5	2011	The pharmacologically active compounds 9-11 with the phenylpiperazine moiety showed affinity for alpha(1)-receptors (K(i) = 0.143-0.383 muM), but the other compounds were almost (12-15) or completely (8) inactive at this site.	phenylpiperazine	53-69	latexin	Homo sapiens	136-139
21721047-4	2011	However, the phenylpiperazine linker group was dramatically more mobile in Mcl-1 compared to either Bcl-x(L) or Bcl-2.	phenylpiperazine	13-29	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	75-80
21721047-4	2011	However, the phenylpiperazine linker group was dramatically more mobile in Mcl-1 compared to either Bcl-x(L) or Bcl-2.	phenylpiperazine	13-29	BCL2 apoptosis regulator	Homo sapiens	112-117
21163968-7	2011	Targeted chemical modification of the phenylpiperazine moiety at the site of its interaction with the residue His393(6.55) led to the functionally selective ligand {3-[4-(2,3-dihydro-benzofuran-7-yl)-piperazin-1-yl]-propyl}-pyrazol[1,5-a]pyridine-3-carboxamide (FAUC350) that has distinct signaling profiles toward adenylyl cyclase and ERK1/2.	phenylpiperazine	38-54	mitogen-activated protein kinase 3	Homo sapiens	336-342
19388677-1	2009	In an effort to discover novel druglike NK(1) receptor antagonists a new series of suitably substituted C-phenylpiperazine derivatives was identified by an appropriate chemical exploration of related N-phenylpiperazine analogues, with the specific aim to maximize their in vitro affinity and optimize in parallel their pharmacokinetic profile.	phenylpiperazine	200-218	tachykinin receptor 1	Homo sapiens	40-54
16412632-0	2006	BACE-1 inhibitory activities of new substituted phenyl-piperazine coupled to various heterocycles: chromene, coumarin and quinoline.	phenylpiperazine	48-65	beta-secretase 1	Homo sapiens	0-6
18220971-0	2008	Studies on the structure-activity relationship of the basic amine of phenylpiperazines as melanocortin-4 receptor antagonists.	phenylpiperazine	69-86	melanocortin 4 receptor	Homo sapiens	90-113
17994683-0	2007	Design, synthesis, in vitro, and in vivo characterization of phenylpiperazines and pyridinylpiperazines as potent and selective antagonists of the melanocortin-4 receptor.	phenylpiperazine	61-78	melanocortin 4 receptor	Mus musculus	147-170
18082872-1	2008	Previous studies have demonstrated that LASSBio-579 and LASSBio-581, two N-phenylpiperazine derivatives designed for the treatment of schizophrenia, are presynaptic dopamine D(2) receptor agonists that induce a hypothermic effect in mice that is not mediated by dopamine receptor activation.	phenylpiperazine	73-91	dopamine receptor D2	Mus musculus	165-187
18037910-8	2008	The guinea pig P2X(7) receptor possessed higher affinity for 1-[N,O-bis(5-isoquinoline sulphonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine (KN62), suramin and Coomassie Brilliant Blue than human or rat P2X(7) receptors suggesting that it is pharmacologically different to other rodent or human P2X(7) receptors.	phenylpiperazine	119-136	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	15-30
17585854-5	2007	The most potent P2X7 receptor antagonist identified in this study (compound 4g) contains an o-fluorine substituent on the phenylpiperazine moiety and had an IC50 of 12.1 nM.	phenylpiperazine	122-138	purinergic receptor P2X 7	Homo sapiens	16-29
16919461-0	2006	Novel potent neuropeptide Y Y5 receptor antagonists: synthesis and structure-activity relationships of phenylpiperazine derivatives.	phenylpiperazine	103-119	neuropeptide Y receptor Y5	Homo sapiens	28-39
16919461-1	2006	A series of phenylpiperazine derivatives were synthesized and evaluated for their neuropeptide Y (NPY) Y5 receptor antagonistic activities.	phenylpiperazine	12-28	neuropeptide Y receptor Y5	Homo sapiens	82-114
16919461-3	2006	Subsequent optimization of the phenylpiperazine template by substitution of the phenyl moiety resulted in a series of (2-methanesulfonamidephenyl)piperazine derivatives that showed potent binding affinity and antagonistic activity for the Y5 receptor.	phenylpiperazine	31-47	neuropeptide Y receptor Y5	Homo sapiens	239-250
16412632-2	2006	Here, we report a new series of analogues based on the phenyl-piperazine scaffold coupled to various heterocyclic moieties, which demonstrate improved inhibitory activities on BACE-1 (FRET assay) compared to already known naphthyl counterparts.	phenylpiperazine	55-72	beta-secretase 1	Homo sapiens	176-182
11670871-11	1999	Complex 8, (CuCN)(phpip), crystallizes in the monoclinic space group P2(1)/cwith unit cell dimensions a = 17.8819(3) A, b = 6.9190(1) A, c = 8.6972(1) A, beta = 96.720(1) degrees, and Z = 4.	phenylpiperazine	18-23	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	69-74
14552781-1	2003	Incorporation of substituted phenyl piperazine privileged structures into a known MC4 specific dipeptoid consensus sequence resulted in a series of potent (EC(50)=24 nM) and selective MC4-R agonists.	phenylpiperazine	29-46	melanocortin 4 receptor	Homo sapiens	184-189
15107597-1	2003	Our aim was to specify the 5-HT(2) subtype selectivity of EGIS-7625 (1-benzyl-4-[(2-nitro-4-methyl-5-amino)-phenyl]-piperazine), a new 5-HT(2B) ligand, in receptor binding studies and characterize its pharmacology at 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors in in vivo experiments and in isolated organs, in vitro.	phenylpiperazine	106-126	5-hydroxytryptamine receptor 2B	Homo sapiens	135-142
12204476-1	2002	Compounds in which N-phenylpiperazines were linked by a propyloxy chain to position 6 or 7 of a coumarin ring were designed and synthesised, and their affinities for 5-HT(1A) and D(2A) receptors were determined by radioligand binding assays.	phenylpiperazine	19-38	5-hydroxytryptamine receptor 1A	Homo sapiens	166-173
10853650-0	2000	Novel phenylpiperazine derivatives as dual cytokine regulators with TNF-alpha suppressing and IL-10 augmenting activity.	phenylpiperazine	6-22	tumor necrosis factor	Mus musculus	68-77
10853650-0	2000	Novel phenylpiperazine derivatives as dual cytokine regulators with TNF-alpha suppressing and IL-10 augmenting activity.	phenylpiperazine	6-22	interleukin 10	Mus musculus	94-99
10853650-1	2000	Phenylpiperazine derivatives were synthesized as dual cytokine regulators with TNF-alpha suppressing and IL-10 augmenting activity.	phenylpiperazine	0-16	tumor necrosis factor	Mus musculus	79-88
10853650-1	2000	Phenylpiperazine derivatives were synthesized as dual cytokine regulators with TNF-alpha suppressing and IL-10 augmenting activity.	phenylpiperazine	0-16	interleukin 10	Mus musculus	105-110
10397500-2	1999	A test series of 32 phenylpiperazines III with affinity for 5-HT1A and alpha1 receptors was subjected to QSAR analysis using artificial neural networks (ANNs), in order to get insight into the structural requirements that are responsible for 5-HT1A/alpha1 selectivity.	phenylpiperazine	20-37	5-hydroxytryptamine receptor 1A	Homo sapiens	60-66
10397500-2	1999	A test series of 32 phenylpiperazines III with affinity for 5-HT1A and alpha1 receptors was subjected to QSAR analysis using artificial neural networks (ANNs), in order to get insight into the structural requirements that are responsible for 5-HT1A/alpha1 selectivity.	phenylpiperazine	20-37	5-hydroxytryptamine receptor 1A	Homo sapiens	242-248
11888550-0	2002	Specific labelling of serotonin 5-HT(1B) receptors in rat frontal cortex with the novel, phenylpiperazine derivative, [3H]GR125,743.	phenylpiperazine	89-105	5-hydroxytryptamine receptor 1B	Rattus norvegicus	32-39
11170629-2	2001	A classical quantitative structure-activity relationship (Hansch) study and artificial neural networks (ANNs) have been applied to a training set of 32 substituted phenylpiperazines with affinity for 5-HT(1A) and alpha(1)-adrenergic receptors, to evaluate the structural requirements that are responsible for 5-HT(1A)/alpha(1) selectivity.	phenylpiperazine	164-181	5-hydroxytryptamine receptor 1A	Homo sapiens	200-207
9513604-2	1998	The structural contributions to D2/D3 and 5-HT1A receptor binding of the aminopyrimidine, cycloalkyl, and phenylpiperazine portions of the molecule were examined.	phenylpiperazine	106-122	immunoglobulin heavy diversity 2-15	Homo sapiens	32-48
34536431-10	2022	In conclusion, oral administration of the newly synthesized phenylpiperazines produced anxiolytic- and antidepressant-like effects in behavioral tests, putatively in part through the activation of 5-HT1A receptors.	phenylpiperazine	60-77	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	197-203
9364416-0	1997	Synthesis of several substituted phenylpiperazines behaving as mixed D2/5HT1A ligands.	phenylpiperazine	33-50	5-hydroxytryptamine receptor 1A	Bos taurus	72-77
8960552-2	1996	The synthesis of 1-phenylpiperazines, linked in the alpha or beta position of the tetralin moiety on the terminal part of the N-4 alkyl chain, and their radioligand binding affinities for 5-HT(1A), 5-HT(2A), D-1, D-2, alpha1, and alpha2 receptors along with SAR studies on the 5-HT(1A) receptor are reported.	phenylpiperazine	17-36	5-hydroxytryptamine receptor 1A	Homo sapiens	188-195
8960552-2	1996	The synthesis of 1-phenylpiperazines, linked in the alpha or beta position of the tetralin moiety on the terminal part of the N-4 alkyl chain, and their radioligand binding affinities for 5-HT(1A), 5-HT(2A), D-1, D-2, alpha1, and alpha2 receptors along with SAR studies on the 5-HT(1A) receptor are reported.	phenylpiperazine	17-36	5-hydroxytryptamine receptor 2A	Homo sapiens	200-205
8960552-2	1996	The synthesis of 1-phenylpiperazines, linked in the alpha or beta position of the tetralin moiety on the terminal part of the N-4 alkyl chain, and their radioligand binding affinities for 5-HT(1A), 5-HT(2A), D-1, D-2, alpha1, and alpha2 receptors along with SAR studies on the 5-HT(1A) receptor are reported.	phenylpiperazine	17-36	5-hydroxytryptamine receptor 1A	Homo sapiens	277-294
8960552-4	1996	The highest affinity (IC50 = 0.50 nM) and selectivity for the 5-HT(1A) receptor were showed by 1-phenylpiperazine 2a with a three-membered alkyl chain bearing a 5-methoxytetralin-1-yl ring in the omega position.	phenylpiperazine	95-113	5-hydroxytryptamine receptor 1A	Homo sapiens	62-79
8923668-1	1996	The in vivo imaging of a novel iodinated phenylpiperazine derivative for 5-HT1A receptors, [123I]p-MPPI (4-(2"-methoxy-)phenyl-1-[2"-(n-2"-pyridinyl)-p-iodobenzamido-] ethyl-piperazine), using single photon emission computed tomography (SPECT), was evaluated in nonhuman primates.	phenylpiperazine	41-57	5-hydroxytryptamine receptor 1A	Homo sapiens	73-79
8767112-3	1996	It has also been found that the two 1-phenylpiperazine derivatives 32 and 36 are new selective 5-HT2A receptor ligands (Ki = 34 and 37 nM, respectively), whereas the derivative of 1-(o-methoxyphenyl)piperazine (38) is a new, highly potent 5-HT1A receptor ligand (Ki = 0.51 nM) with a moderate affinity for 5-HT2A receptors (Ki = 213 nM).	phenylpiperazine	36-54	5-hydroxytryptamine receptor 2A	Homo sapiens	95-110
8767112-3	1996	It has also been found that the two 1-phenylpiperazine derivatives 32 and 36 are new selective 5-HT2A receptor ligands (Ki = 34 and 37 nM, respectively), whereas the derivative of 1-(o-methoxyphenyl)piperazine (38) is a new, highly potent 5-HT1A receptor ligand (Ki = 0.51 nM) with a moderate affinity for 5-HT2A receptors (Ki = 213 nM).	phenylpiperazine	36-54	5-hydroxytryptamine receptor 2A	Homo sapiens	97-101
9436302-0	1997	Structure and serotonin 5-HT2C receptor activity of ortho- and meta-substituted phenylpiperazines.	phenylpiperazine	80-97	5-hydroxytryptamine receptor 2C	Homo sapiens	14-39
9436302-1	1997	The structural characteristics of ortho- and meta-substituted phenylpiperazines have been investigated in order to understand their actions at the serotonin 5-HT2C receptor.	phenylpiperazine	62-79	5-hydroxytryptamine receptor 2C	Homo sapiens	147-172
9436302-4	1997	The activities of several phenylpiperazines, in combination with their crystal structures and conformational characteristics, lead to the hypothesis that the conformation for which the piperazine ring and the phenyl ring are approximately co-planar should be the 5-HT2C receptor "activating" conformation.	phenylpiperazine	26-43	5-hydroxytryptamine receptor 2C	Homo sapiens	263-269
9105540-7	1997	Derivatives of 1-(2-pyridyl)piperazine 1b and 2a and of 1-phenylpiperazine 1a expressed moderate to low affinity for both D-2 and 5-HT1A receptors, while 1-(2-pyridyl)-piperazines 3b and 4b and 4-(1-phenylethyl)-1-(1-naphthyl)-piperazine 10 were moderate [3H]spiperone, but potent 8-OH-[3H]DPAT competitors.	phenylpiperazine	56-74	5-hydroxytryptamine receptor 1A	Bos taurus	130-136
8951963-4	1996	On the other hand, long-term treatment with the monoamine oxidase type-A inhibiting antidepressant, clorgyline (1 mg/kg/day) and the alpha 2-noradrenergic antagonists, yohimbine and 1-phenylpiperazine (1 mg/kg/day, each) did not modify clonidine"s effect.	phenylpiperazine	182-200	monoamine oxidase A	Rattus norvegicus	48-72
8748393-2	1995	Three structural classes of compounds have been described to stimulate increases in phosphoinositide (PI) hydrolysis at the 5-HT2C receptor site: phenylpiperazines, phenylalkylamines, and indolamines.	phenylpiperazine	146-163	5-hydroxytryptamine receptor 2C	Homo sapiens	124-130
8064803-3	1994	Structure-affinity relationship (SAR) studies for the 5-HT1A receptor site are presented for two series of heterobicyclic phenylpiperazines with N4-aralkyl substituents: 4-aralkyl derivatives of 1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazine (3) and 1-(benzo[b]furan-7-yl)piperazine (4).	phenylpiperazine	122-139	5-hydroxytryptamine receptor 1A	Homo sapiens	54-69
8365456-1	1993	The novel phenylpiperazine derivative, (+/-)-WAY100135 (N-tert-butyl-3-(4-(2-methoxyphenyl)piperazin-1-yl)-2-phenylpro pionamide dihydrochloride), is a selective antagonist at both somatodendritic and postsynaptic 5-HT1A receptors.	phenylpiperazine	10-26	5-hydroxytryptamine receptor 1A	Rattus norvegicus	214-220
3982214-0	1985	5-HT-1a and 5-HT-1b selectivity of two phenylpiperazine derivatives: evidence for 5-HT-1b heterogeneity.	phenylpiperazine	39-55	5-hydroxytryptamine receptor 1A	Rattus norvegicus	0-7
34604625-0	2021	Molecular Dynamics Simulations Identify Tractable Lead-like Phenyl-Piperazine Scaffolds as eIF4A1 ATP-competitive Inhibitors.	phenylpiperazine	60-77	eukaryotic translation initiation factor 4A1	Homo sapiens	91-97
34073405-0	2021	Evaluation of Substituted N-Phenylpiperazine Analogs as D3 vs. D2 Dopamine Receptor Subtype Selective Ligands.	phenylpiperazine	26-44	dopamine receptor D2	Homo sapiens	63-83
34073405-1	2021	N-phenylpiperazine analogs can bind selectively to the D3 versus the D2 dopamine receptor subtype despite the fact that these two D2-like dopamine receptor subtypes exhibit substantial amino acid sequence homology.	phenylpiperazine	0-18	dopamine receptor D2	Homo sapiens	69-89
22156500-1	1989	The new phenylpiperazine derivative flesinoxan, a potent and selective serotonin(1A) (5-HT(1A)) agonist, was examined under a procedure that has proved to be a reliable and sensitive method for detecting novel anxiolytic drugs believed to produce their effects at the 5-HT( 1A) receptor subtype.	phenylpiperazine	8-24	5-hydroxytryptamine receptor 1A	Homo sapiens	86-93
22156500-1	1989	The new phenylpiperazine derivative flesinoxan, a potent and selective serotonin(1A) (5-HT(1A)) agonist, was examined under a procedure that has proved to be a reliable and sensitive method for detecting novel anxiolytic drugs believed to produce their effects at the 5-HT( 1A) receptor subtype.	phenylpiperazine	8-24	5-hydroxytryptamine receptor 1A	Homo sapiens	268-286
2879202-0	1986	In vitro receptor specificity of the 5HT1A selective phenylpiperazine, LY165163.	phenylpiperazine	53-69	5-hydroxytryptamine receptor 1A	Rattus norvegicus	37-42
3982214-0	1985	5-HT-1a and 5-HT-1b selectivity of two phenylpiperazine derivatives: evidence for 5-HT-1b heterogeneity.	phenylpiperazine	39-55	5-hydroxytryptamine receptor 1B	Rattus norvegicus	12-19
3982214-0	1985	5-HT-1a and 5-HT-1b selectivity of two phenylpiperazine derivatives: evidence for 5-HT-1b heterogeneity.	phenylpiperazine	39-55	5-hydroxytryptamine receptor 1B	Rattus norvegicus	82-89
32086055-2	2020	The compounds exhibited high affinity for the 5-HT1A receptor, (especially 4dKi = 0.4 nM) which depended on the substitution pattern at the phenylpiperazine moiety.	phenylpiperazine	140-156	5-hydroxytryptamine receptor 1A	Homo sapiens	46-61
32631504-2	2020	Herein we report the discovery of a series of new SIRT6 inhibitors containing the skeleton 1-phenylpiperazine.	phenylpiperazine	91-109	sirtuin 6	Mus musculus	50-55
33988991-3	2021	Here, we examine the molecular basis for the high affinity D3R binding and D3R vs D2R binding selectivity of substituted phenylpiperazine thiopheneamides.	phenylpiperazine	121-137	dopamine receptor D3	Homo sapiens	75-78
33988991-3	2021	Here, we examine the molecular basis for the high affinity D3R binding and D3R vs D2R binding selectivity of substituted phenylpiperazine thiopheneamides.	phenylpiperazine	121-137	dopamine receptor D2	Homo sapiens	82-85
30010318-3	2018	Our goal was to investigate how the composition and size of the nonaromatic ring structure at the piperazine position of substituted phenylpiperazine analogues might influence binding affinity at the human D2 and D3 dopamine receptors.	phenylpiperazine	133-149	dopamine receptor D2	Homo sapiens	206-234
31989362-10	2020	Pre-incubation of mucosae with two 5-HT4 receptor antagonists, a loop diuretic and a myosin light chain kinase inhibitor, reduced the permeation enhancement capacity of PPZ and 1-4-MPP for [14C]-mannitol.	phenylpiperazine	169-172	myosin light chain kinase	Rattus norvegicus	85-110
32560608-2	2020	This study was undertaken to identify if indol-2-carboxylic acid esters containing N-phenylpiperazine moiety possess acetylcholinesterase and butyrylcholinesterase inhibitory activity.	phenylpiperazine	83-101	butyrylcholinesterase	Homo sapiens	142-163
31214037-1	2019	LASSBio-579, an N-phenylpiperazine antipsychotic lead compound, has been previously reported as a D2 receptor (D2R) ligand with antipsychotic-like activities in rodent models of schizophrenia.	phenylpiperazine	16-34	dopamine receptor D2	Homo sapiens	98-109
31214037-1	2019	LASSBio-579, an N-phenylpiperazine antipsychotic lead compound, has been previously reported as a D2 receptor (D2R) ligand with antipsychotic-like activities in rodent models of schizophrenia.	phenylpiperazine	16-34	dopamine receptor D2	Homo sapiens	111-114